NKore BioTherapeutics is a cellular-based biotherapeutics company focused on the early detection, prevention, and treatment of cancer. Our technology is based on a proprietary method of activating natural killer (NK) cells, creating Supercharged Natural Killer (sNK) cells used as a novel oncology immunotherapy platform. Our proprietary activation method enhances NK cells’ overall effectiveness, making them significantly more potent (i.e., they are more cytotoxic to the cancer cells), while reducing the likelihood of tumor regeneration and metastasis.
The technology was developed by Dr. Anahid Jewett, the Company’s co-founder and Chief Scientific Advisor. Based on positive preclinical results, we believe that Dr. Jewett’s 35-plus years of researching NK cell function has resulted in the development of a novel and effective cancer immunotherapy. NKore’s current focus is to translate and replicate the positive preclinical results into human clinical trials and achieve marketing approval. Patients are actively receiving treatments and showing early signs of a positive response with no negative side effects currently reported.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Los Angeles , Ca 91423, Us
- Industry
- Biotechnology
- Website
- http://www.NKore.com
- HQ
- Los Angeles , CA
Nkore Biotherapeutics Questions
Nkore Biotherapeutics's website is http://www.NKore.com
Nkore Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/nkore
Nkore Biotherapeutics has
8 employees.
View email and phone details for 8
employees at Nkore Biotherapeutics.
Nkore Biotherapeutics's industry is
Biotechnology
Nkore Biotherapeutics's top competitors are
Arcutis Biotherapeutics, Inc. (Nasdaq: Arqt),
Kura Oncology, Inc.,
M7 Healthcare Accelerator,
Tentarix Biotherapeutics,
Velius Enterprise,
Concarlo Therapeutics,
Nkorr Technologies Pvt Ltd,
Crescent Biopharma,
Orca Bio,
Compugen.
Nkore Biotherapeutics's categories are Biotechnology
Nkore Biotherapeutics's founding year is 2018
